CN105025925A - 抗-催乳素受体抗体制剂 - Google Patents

抗-催乳素受体抗体制剂 Download PDF

Info

Publication number
CN105025925A
CN105025925A CN201480016050.7A CN201480016050A CN105025925A CN 105025925 A CN105025925 A CN 105025925A CN 201480016050 A CN201480016050 A CN 201480016050A CN 105025925 A CN105025925 A CN 105025925A
Authority
CN
China
Prior art keywords
prlr
prlr antibody
formulation
antibody
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480016050.7A
Other languages
English (en)
Chinese (zh)
Inventor
马星航
牛健杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CN105025925A publication Critical patent/CN105025925A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201480016050.7A 2013-03-15 2014-03-14 抗-催乳素受体抗体制剂 Pending CN105025925A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15
US61/799629 2013-03-15
PCT/US2014/028078 WO2014143909A1 (en) 2013-03-15 2014-03-14 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
CN105025925A true CN105025925A (zh) 2015-11-04

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480016050.7A Pending CN105025925A (zh) 2013-03-15 2014-03-14 抗-催乳素受体抗体制剂

Country Status (10)

Country Link
US (2) US9023357B2 (https=)
EP (1) EP2968538A1 (https=)
JP (1) JP2016515515A (https=)
CN (1) CN105025925A (https=)
AR (1) AR095496A1 (https=)
CA (1) CA2906101A1 (https=)
HK (1) HK1215175A1 (https=)
TW (1) TW201513882A (https=)
UY (1) UY35460A (https=)
WO (1) WO2014143909A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
SG10202012778YA (en) 2015-12-18 2021-01-28 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3518971A4 (en) 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN112020365A (zh) * 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
TW202432601A (zh) 2022-11-07 2024-08-16 美商上游生物公司 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CN101611058A (zh) * 2006-08-18 2009-12-23 诺华有限公司 Prlr特异性抗体及其用途
CN102458469A (zh) * 2009-05-04 2012-05-16 艾博特生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
CN102858804A (zh) * 2009-12-10 2013-01-02 拜耳知识产权有限责任公司 中和催乳素受体抗体及其治疗用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
CN105037549B (zh) * 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
ES2531385T3 (es) * 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101611058A (zh) * 2006-08-18 2009-12-23 诺华有限公司 Prlr特异性抗体及其用途
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CN102458469A (zh) * 2009-05-04 2012-05-16 艾博特生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
CN102858804A (zh) * 2009-12-10 2013-01-02 拜耳知识产权有限责任公司 中和催乳素受体抗体及其治疗用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
邢光东等: "鹅催乳素受体多克隆抗体制备及组织表达分析", 《南京农业大学学报》 *

Also Published As

Publication number Publication date
WO2014143909A1 (en) 2014-09-18
HK1215175A1 (zh) 2016-08-19
CA2906101A1 (en) 2014-09-18
US9023357B2 (en) 2015-05-05
UY35460A (es) 2014-10-31
TW201513882A (zh) 2015-04-16
JP2016515515A (ja) 2016-05-30
US20140271659A1 (en) 2014-09-18
US20160002342A1 (en) 2016-01-07
AR095496A1 (es) 2015-10-21
EP2968538A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CN104736175B (zh) 抗催乳素受体抗体制剂
US9023357B2 (en) Anti-prolactin receptor antibody formulations
CN104684933B (zh) 抗体和蛋白质制剂
TW201907951A (zh) 用於男性及女性型態掉髮之催乳素受體抗體
HK40020981A (en) Anti-prolactin receptor antibody formulations
HK40020980A (en) Anti-prolactin receptor antibody formulations
HK1207316B (zh) 抗催乳素受体抗体制剂
JP2023532203A (ja) アクチビンａ抗体製剤及びその使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215175

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151104

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215175

Country of ref document: HK